What is the recommended non‑occupational post‑exposure prophylaxis (nPEP) regimen and testing schedule for HIV exposure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

HIV Non-Occupational Post-Exposure Prophylaxis (nPEP): Regimen and Testing

For adults and adolescents requiring nPEP, initiate bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as a single-tablet regimen for 28 days, starting within 72 hours (ideally within 24 hours) of exposure, with HIV testing at baseline, 4-6 weeks, and 12 weeks post-exposure. 1

When to Prescribe nPEP

Indications:

  • Recommend nPEP when exposure occurred ≤72 hours ago AND presents substantial HIV transmission risk (anal/vaginal intercourse without condom) AND source has HIV without sustained viral suppression or viral load status unknown 1
  • Case-by-case determination when exposure occurred ≤72 hours ago with substantial transmission risk BUT source HIV status is unknown 1
  • Do NOT recommend nPEP if:
    • Exposure presents no substantial risk (oral-genital contact, intact condom use) 1
    • Source is known HIV-negative 1
    • Source has sustained viral suppression 1
    • Exposed person was taking PrEP as recommended 1

    • 72 hours since exposure 1

Stop nPEP immediately if source is determined to not have HIV at any point during the 28-day course 1

Preferred Medication Regimens

The 2025 CDC guidelines provide two preferred options 1:

Option 1 (Preferred): Bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) - single daily tablet

Option 2 (Preferred): Dolutegravir (DTG) PLUS (tenofovir alafenamide [TAF] OR tenofovir disoproxil fumarate [TDF]) PLUS (emtricitabine [FTC] OR lamivudine [3TC])

Regimen selection should account for:

  • Renal dysfunction (favor TAF over TDF if CrCl 30-60 mL/min)
  • Hepatic dysfunction
  • Pregnancy status
  • Drug interactions with current medications
  • Prior antiretroviral exposure (including long-acting injectable PrEP in past 12 months)
  • Source's resistance history if known
  • Pill burden and adherence factors 1

The single-tablet BIC/FTC/TAF regimen offers superior convenience and likely better adherence compared to multi-pill alternatives, which is critical given that completion of the full 28-day course is essential for efficacy 2.

HIV Testing Schedule

Baseline (before starting nPEP):

  • Rapid HIV antibody test OR laboratory-based HIV Ag/Ab combination test 1
  • Do NOT delay first nPEP dose waiting for laboratory results 1
  • Add diagnostic HIV NAT if person received long-acting injectable PrEP in past 12 months 1

Interim testing at 4-6 weeks:

  • Laboratory-based HIV Ag/Ab test PLUS diagnostic HIV NAT 1
  • May defer this testing ONLY if nPEP started within 24 hours of exposure AND patient missed no doses 1

Final testing at 12 weeks:

  • Laboratory-based HIV Ag/Ab combination immunoassay PLUS diagnostic HIV NAT 1
  • This is the definitive test to rule out HIV acquisition

Critical Implementation Points

Timing is everything:

  • First dose should be given as soon as possible, ideally within 24 hours 1
  • Can initiate up to 72 hours post-exposure, but efficacy decreases with delay 1
  • Evidence is insufficient for initiation >72 hours, though some experts argue for case-by-case consideration 1

Clinical assessment before prescribing:

  • Medical comorbidities (especially renal, hepatic, bone disease)
  • Current medications (check for drug interactions)
  • Allergies
  • Pregnancy status
  • Previous ARV exposure 1

Follow-up schedule:

  • 24 hours post-initiation (remote or in-person visit for adherence support) 1
  • 4-6 weeks (clinical follow-up + HIV testing)
  • 12 weeks (final HIV testing)

Common Pitfalls to Avoid

  1. Delaying initiation for laboratory results - Start immediately with rapid testing; do not wait for comprehensive labs 1

  2. Missing the long-acting PrEP history - Patients with cabotegravir exposure in past 12 months need baseline NAT testing in addition to Ag/Ab testing, as they may have breakthrough infection with delayed antibody response 1

  3. Prescribing nPEP for low-risk exposures - Oral-genital contact without ejaculation or exposures with intact condoms do not warrant nPEP 1

  4. Failing to transition to PrEP - For patients with ongoing HIV exposure risk, transition directly from nPEP to PrEP after negative HIV testing at 28 days 1

  5. Inadequate adherence support - Contemporary regimens are well-tolerated, but the 28-day completion is critical; early follow-up at 24 hours helps address side effects and reinforce adherence 1

Transition to PrEP

Immediate transition from nPEP to PrEP is beneficial for persons with anticipated repeat or ongoing HIV exposures 1. Perform HIV testing at completion of the 28-day nPEP course, and if negative, promptly transition to a recommended PrEP regimen without a gap in coverage.

Expert Consultation

For complex cases (pregnancy, known source resistance, unusual exposures), consult the National Clinical Consultation Center PEPline at 888-448-4911 or visit https://nccc.ucsf.edu/clinician-consultation/pep-post-exposure-prophylaxis 1

References

2
Research

The 2025 Centers for Disease Control and Prevention Nonoccupational HIV Postexposure Prophylaxis Guidelines: Updated Regimens and Remaining Questions.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026

Related Questions

What is the recommended post‑exposure prophylaxis (PEP) regimen for HIV after a needle‑prick injury, including the specific drugs, dosages, duration, and follow‑up HIV testing schedule?
What are the recommended drugs and dosing for HIV post‑exposure prophylaxis (PEP) in adults, adolescents, and children?
What are the recommended two‑drug and three‑drug regimens for HIV post‑exposure prophylaxis, including dosing for adults and children?
What is the recommended 28‑day HIV post‑exposure prophylaxis regimen for adults, adolescents, and children based on weight categories?
How effective is HIV post‑exposure prophylaxis (PEP) when started promptly, and what is the recommended regimen?
What loading dose of colistimethate sodium (colistin) should be administered to a typical 70‑kg adult with normal renal function?
What does an elevated NT‑proBNP indicate in a 73‑year‑old man with a preserved ejection fraction of 60‑65% and grade 1 diastolic dysfunction?
Which baseline laboratory tests should be obtained after a potential exposure (e.g., needle‑stick or unprotected sexual contact) to assess human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV), syphilis, and other sexually transmitted infections (STIs), and to evaluate suitability for post‑exposure prophylaxis?
What antibiotic is appropriate for a carbuncle with black necrotic tissue on top?
What is a comprehensive management guide for a family medicine specialist caring for patients with HIV/AIDS, including antiretroviral therapy initiation, baseline laboratory evaluation, vaccinations, opportunistic infection prophylaxis, monitoring, and follow‑up?
Can patients with an estimated glomerular filtration rate of 11 ml/min/1.73 m² receive standard sedation with midazolam (a benzodiazepine) and fentanyl (an opioid) during colonoscopy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.